Warum steigt der Aktienkurs von PFIZER?
Bullen sagen
Oncology clinical trial
A positive Phase 3 readout for mevrometostat in advanced prostate cancer could establish a new standard of care and materially increase Pfizer's oncology revenue prospects.
Obesity franchise development
Strong late-stage and combination data for berobenatide and the GLP-1/amylin monthly-dosing program could substantially expand the obesity treatment franchise and reshape growth expectations.
Cost savings and margin expansion
A large cost-savings and manufacturing optimization program is expected to improve margins and operating leverage, supporting earnings resilience despite revenue headwinds.
COVID product sales pressure
Ongoing weakness and downward revisions in COVID product sales continue to pressure revenue and may constrain near-term upside to company guidance.
Clinical setbacks and concentration risk
A recent clinical failure in a lung cancer program and delays in key late-stage readouts highlight pipeline concentration risk and raise downside if pivotal trials miss expectations.
Acquisition and financial management uncertainty
Persistent questions about the value and timing of the Seagen acquisition combined with finance leadership turnover create uncertainty around capital allocation and could dampen investor confidence.
